Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis

American Heart Journal

Volumn 134, Issue 4, 1997, Pages 764-771

  Lip, G Y H ^a   Blann, A D ^a   Jones, A F ^a   Beevers, D G ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; FIBRIN; FIBRINOGEN; FOLLITROPIN; LIPID; LIPOPROTEIN A; LUTEINIZING HORMONE; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; EARLY MENOPAUSE; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN THERAPY; FEMALE; HEMODYNAMICS; HEMOSTASIS; HUMAN; HYSTERECTOMY; LONGITUDINAL STUDY; METRORRHAGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SALPINGOOOPHORECTOMY; THROMBOCYTE FUNCTION;

EID: 0030708589     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(97)70062-0     Document Type: Article

References (42)

1. GYH Lip J Zarifis DG. Beevers Concurrent risk factors F Messerli Hypertension and other cardiovascular risk factors after the menopause. 1995 Marcel Dekker New York 113 137
2. E Ernst KL. Resch Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature Ann Intern Med 118 1993 956 963
3. S Dawson A. Henney The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review Atherosclerosis 95 1992 105 117
4. GYH Lip GDO Lowe Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci 89 1995 205 214
5. GYH Lip AF. Jones Lipoprotein (a) and vascular disease: thrombogenesis and atherogenesis Q J Med 88 1995 529 539
6. AD Blann DA. Taberner A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 90 1995 244 248
7. GYH Lip AD. Blann von Willebrand factor and its relevance to cardiovascular disease Br Heart J 74 1995 580 583
8. AD Blann M Dobrotova P Kubisz CN. McCollum von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis Thromb Haemost 74 1995 626 630
9. BH Chong B Murray MC Berndt LC Dunlop T Brighton CN. Chesterman Plasma P-selectin is increased in thrombotic consumptive platelet disorders Blood 83 1994 1535 1541
10. J Petrie M Jamieson E O’Brien W Littler P Padfield M de Swiet Working party on blood pressure measurement videotape “blood pressure measurement.” BMJ 1990
11. NL. Esmon Thrombomodulin Semin Thromb Haemost 13 1987 454 463
12. MS Marsh D Crook SI Whitcroft M Worthington MI Whitehead JC. Stevenson Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins Obstet Gynecol 83 1994 19 23
13. AA Nabulsi AR Folsom A White Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women, the Atherosclerosis Risk in Communities Study Investigators N Engl J Med 328 1993 1069 1075
14. CJ Kim HC Jang DH Cho YK. Min Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women Arterioscler Thromb 14 1994 275 281
15. MR Soma I Osnago-Gadda R Paoletti The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women Arch Intern Med 153 1993 1462 1468
16. JL Jenner JM Ordovas S Lamon-Fava Effects of age, sex and menopausal status on plasma lipoprotein (a) levels: the Framingham Offspring study Circulation 87 1993 1135 1141
17. M Notelovitz CS Kitchens MD. Ware Coagulation and fibrinolysis in estrogen-treated surgically menopausal women Obstet Gynecol 63 1984 621 624
18. EN Meilahn LH Kuller KA Matthews JE. Kiss Hemostatic factors according to menopausal status and use of hormone replacement therapy Ann Epidemiol 2 1992 445 455
19. OC Gebara MA Mittleman P Sutherland Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study Circulation 91 1995 1952 1958
20. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 273 1995 199 208
21. Medical Research Council’s General Practice Research Framework Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy Br Med J 312 1996 473 478
22. JWJ van Wersch JMH Ubachs A van den Ende A. van Enk The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women Eur J Clin Chem Clin Biochem 32 1994 449 453
23. YG Caine KA Bauer S Barzegar Coagulation activation following estrogen administration to postmenopausal women Thromb Haemost 68 1992 392 395
24. UB Kroon SL. Tengborn The effects of transdermal estradiol and oral conjugated estrogens on haemostatic variables Thromb Haemost 71 1994 420 423
25. P Collins GM Rosano PM Sarrel 17 Beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease Circulation 92 1995 24 30
26. JK Williams MR Adams HS. Klopfenstein Estrogen modulates responses of atherosclerotic coronary arteries Circulation 81 1990 1680 1687
27. RJ Bing A. Conforto Reversal of acetylcholine effect on atherosclerotic coronary arteries by estrogen: pharmacologic phenomenon of clinical importance? J Am Coll Cardiol 20 1992 458 459
28. RR Magness CR Rosenfeld Local and systemic estradiol-17β: effects on uterine and systemic vasodilation Am J Physiol 256 1989 E536 E554
29. CR Rosenfeld FH Morriss FC Battaglia FL Makowski G Meschia Effect of estradiol-17β on blood flow to reproductive and non-reproductive tissues in pregnant ewes Am J Obstet Gynecol 124 1976 618 629
30. CW Jiang PM Sarrel DC Lindsay PA Poole-Wilson P Collins Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro Br J Pharmacol 104 1991 1033 1037
31. DM Gilligan DM Badar JA Panza AA Quyyumi RO. Cannon Acute vascular effects of estrogen in postmenopausal women Circulation 90 1994 786 791
32. KF Ganger S Vyas M Whitehead D Crook H Meire S. Campbell Pulsatility index in internal carotid artery in relation to transdermal estradiol and time since menopause Lancet 338 1989 839 842
33. A Pines EZ Fisman Y Levo The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow Am J Obstet Gynecol 164 1991 806 812
34. GMC Rosano PM Sarrel PA Poole-Wilson P. Collins Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease Lancet 342 1993 133 136
35. PE. Belchetz Hormonal treatment of postmenopausal women N Engl J Med 330 1994 1062 1071
36. J Staessen CJ Bulpitt R Fagard P Lijnen A. Amery The influence of menopause on blood pressure J Hum Hypertens 3 1989 427 433
37. DE Grobbee AM van Hemert JP Vandenbroucke A Hofman HA. Valkenburg Importance of body weight in determining rise and level of blood pressure in postmenopausal women J Hypertens 6 suppl 1988 S614 S616
38. C Christiansen MS Christensen C Hagen KE Stocklund I Transbøl Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women Acta Obstet Gynecol Scand 60 1981 407 412
39. T Lind EC Cameron WM Hunter A prospective controlled trial of six forms of hormone replacement therapy given to postmenopausal women Br J Obstet Gynaecol 86 suppl 1979 1 29
40. RI Pfeffer TT Kurosaki SK. Charlton Estrogen use and blood pressure in later life Am J Epidemiol 110 1979 469 478
41. AW von Eiff EJ Plotz KJ Beck A. Czernik The effects of estrogens and progestins on blood pressure regulation of normotensive women Am J Obstet Gynaecol 4 1971 31 47
42. GYH Lip M Beevers D Churchill DG. Beevers Hormone replacement therapy and blood pressure in hypertensive women J Hum Hypertens 8 1994 491 494